loading...| Preferred Name | Tofacitinib | |
| Synonyms |
TOFACITINIB JAK inhibitors: tofacitinib Tasocitinib CP-690,550 Free Base 3-((3R,4R)-4-Methyl-3-(Methyl(7H-Pyrrolo(2,3-D)Pyrimidin-4-yl)Amino)Piperidin-1-yl)-3-Oxopropanenitrile Tofacitinib CP-690550 |
|
| Definitions |
An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C95800 |
|
| CAS_Registry |
477600-75-2 |
|
| Chemical_Formula |
C16H20N6O |
|
| code |
C95800 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191670 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191200 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191387 |
|
| Contributing_Source |
ACC/AHA FDA HemOnc |
|
| DEFINITION |
An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. |
|
| FDA_UNII_Code |
87LA6FU830 |
|
| FULL_SYN |
TOFACITINIB JAK inhibitors: tofacitinib Tasocitinib CP-690,550 Free Base 3-((3R,4R)-4-Methyl-3-(Methyl(7H-Pyrrolo(2,3-D)Pyrimidin-4-yl)Amino)Piperidin-1-yl)-3-Oxopropanenitrile Tofacitinib CP-690550 |
|
| Has_ACC-AHA_SARS2_Authorized_Value |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17998 |
|
| Has_Salt_Form | ||
| label |
Tofacitinib |
|
| NCI_Drug_Dictionary_ID |
759505 |
|
| PDQ_Closed_Trial_Search_ID |
759505 |
|
| PDQ_Open_Trial_Search_ID |
759505 |
|
| Preferred_Name |
Tofacitinib |
|
| prefixIRI |
Thesaurus:C95800 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2930696 |
|
| subClassOf |